EUCTR2014-001208-23-GB进行中（未招募）不适用
A randomised, double blind, placebo controlled, phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy. - FURVA, Version 1.0
Velindre NHS Trust0 个研究点开始时间: 2015年7月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patients meeting all of the following criteria may be included in the trial:
- •1.Adult female patients, aged = 18 years.
- •2.Post-menopausal patients. Post-menopausal can be defined as either of the following criteria:
- •a.Amenorrhoeic throughout AND after therapy with a third generation AI, without a GnRH analogue (eg. goserelin) AND screening FSH and estradiol in institutional post-menopausal ranges.
- •b.Treatment of early or metastatic breast cancer with a third generation AI and GnRH analogue, with discontinuation of the GnRH analogue for at least 6 months AND no resumption of menstruation AND screening FSH and estradiol in institutional post-menopausal ranges.
- •3.Minimum life expectancy of 12 weeks.
- •4.Histological confirmation of ER+ve breast cancer on primary tumour at diagnosis or on biopsy of a metastasis. ER is considered positive if =10% of tumour cells stain positive for ER (whatever the intensity of staining). If no percentage score is available then a Quick (Allred) Score of =4/8 will be considered ER positive.
- •5.Histological confirmation of HER2 negative breast cancer on primary tumour at diagnosis or on biopsy of a metastasis. HER2 is considered negative by IHC if scored 0 or 1+ by Herceptest or similar assay. If HER2 is scored 2+ or 2+/3+ by IHC then HER2 gene amplification must be assessed by FISH/CISH/D-DISH and the ratio of HER2 to CEP17 probes must be <2.0.
- •6.Clinical or histological confirmation of metastatic or locally advanced disease not amenable to curative surgical resection.
- •7.ECOG performance status 0 to 2 with no deterioration over the previous 2 weeks.
- •8.Measurable or non-measurable disease.
- •9.Patient has adequate bone marrow and organ function as defined by the following:
- •a.Absolute Neutrophil Count (ANC) = 1.0 x 109/L.
- •b.Platelets (plts) = 100 x 109/L.
- •c.Haemoglobin (Hgb) = 9 g/dl [Note: any blood transfusion must be >14 days prior to the determination of haemoglobin].
- •d.Prothrombin time (seconds) INR= 1.5 x ULN.
- •e.Potassium, calcium (corrected for serum albumin) and magnesium within normal limits (WNL) for the institution.
- •f.Serum creatinine = 1.5xULN.
- •g.Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5xULN (or < 5.0 x ULN if liver metastases are present).
- •h.Total bilirubin =1.5 times ULN.
- •10.Progressive disease whilst receiving a third generation aromatase inhibitor (exemestane, anastrazole or letrozole) for locally advanced or metastatic BC or relapsed with metastatic disease whilst receiving a third generation AI in the adjuvant setting. The AI does not need to be the last treatment immediately prior to recruitment.
- •11.Radiological or objective clinical evidence of recurrence or progression on or after the last systemic therapy prior to enrolment.
- •12.No more than 3 prior lines of endocrine therapy for ABC. If an attempt to downstage a locally advanced tumour with endocrine therapy was made in the absence of MBC, and the tumour operated upon, then this does not count as a line of therapy for ABC. In contrast, if the tumour remained inoperable then this treatment should be included as a line of therapy for ABC.
- •13.No more than 1 line of cytotoxic chemotherapy for ABC (see inclusion criterion 11 12 for note on definition of lines of therapy).
- •14.Suitable for further endocrine therapy according to the treating clinician.
- •15.Availability of archival tumour sample or fresh biopsy for exploratory analysis.
- •16.Provision of informed consent prior to any study speci
排除标准
- •1.Previous treatment with fulvestrant or inhibitors of the RET pathway.
- •2.Last dose chemotherapy, immunotherapy targeted therapy, biological therapy or tumour embolisation less than 21 days (less than 6 weeks for nitrosurea or mitomycin C) prior to the first dose of study treatment. Note: endocrine (hormone) therapy is not considered a targeted or biological therapy for the purposes of this study. Denosumab and bisphosphonate treatment are accepted concomitant medications as long as they are started at least 14 days prior to study drug commencement.
- •3.Last dose of palliative radiotherapy less than 7 days prior to the first dose of study treatment.
- •4.Rapidly progressive visceral disease not suitable for further endocrine therapy.
- •5.Spinal cord compression or brain/meningeal metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks before starting study treatment.
- •6.Any of the following cardiac criteria:
- •a.Significant cardiac event (e.g., myocardial infarction), superior vena cava syndrome, New York Heart Association (NYHA) classification of heart disease =2 within 12 weeks before randomisation (see Appendix 2), or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia.
- •b.History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE v 4.03 Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Patients with atrial fibrillation controlled by medication are permitted.
- •c.Congenital long QT syndrome.
- •d.History of QT prolongation associated with other medications that required discontinuation of that medication
- •e.QTcB >480msec on screening ECG (Note: The screening ECG must be repeated three times 5 minutes apart. The average QTc from the three screening ECGs must be =480 ms in order for the patient to be eligible for the study). If the average QTc is >480ms, the ECGs may be repeated at least 24 hours later, and the average must be =480 ms.
- •7.Patients with the following electrolyte values (the rational is due to the increased risk of prolonged QTc):
- •a)Potassium <4.0 mmol/L despite supplementation, or above the CTCAE Grade 1 upper limit, at the time of randomisation.
- •b)Magnesium below the normal range despite supplementation, or above the CTCAE Grade 1 upper limit, at the time of randomisation.
- •c)Calcium (ionised or serum) below the normal range despite supplementation, or above the Grade 1 upper limit, at the time of randomisation. If serum calcium is used, correction should be applied to account for hypoalbuminemia, if present, where the corrected serum calcium (mg/dL) is equal to measured serum Ca (mg/dL) + 0.8 x (4 - serum albumin g/dL).
- •8.Creatinine clearance <30 ml/min (calculated by Cockcroft-Gault formula, see Appendix 4). Patients with creatinine clearance <50 mL/min will start at a permanently reduced vandetanib dose of 200 mg.
- •9.Major surgery (excluding placement of vascular access) within 4 weeks before the first dose of study treatment.
- •10.As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and the effect of different doses of Oralgen House Dust Mite in patients with house dust mite induced allergic rhinoconjunctivitisEUCTR2008-003879-49-GBArtu Biologicals Europe B.V.
进行中（未招募）
不适用
A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and tolerability of Oralgen Birch Pollen immunotherapy in patients with allergic rhinoconjunctivitisAllergic rhinoconjunctivitisMedDRA version: 9.1Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisEUCTR2008-003861-17-SEArtu Biologicals Europe B.V.
已完成
2 期
A Phase IIa safety study of topical R-flurbiprofen in patients with a history of non-melanoma skin canceron-melanoma skin cancerCancer - Non melanoma skin cancerNon-melanoma skin cancerACTRN12606000192583PharmaQest Pty Ltd40
进行中（未招募）
1 期
A randomized, double blind, placebo controlled, phase II, multi-centre pilot study to investigate the effects of vitamin D2 or D3 supplementation on metabolic parameters in people at risk of type 2 diabetes. - Vitamin D Supplementation in People at Risk of Type 2 Diabetes V1.3EUCTR2009-011264-11-GBQueen Mary University of London340
进行中（未招募）
不适用
A randomized, double blind, placebo controlled, phase II, dose-titration trial to explore the safety, tolerability, pharmacokinetic profile and efficacy of M0002 in cirrhotic subjects with ascites and hypo- or normonatremia.Cirrhotic subjects with ascites and hypo- or normonatraemiaMedDRA version: 9.1Level: LLTClassification code 10009213Term: Cirrhosis of liverMedDRA version: 9.1Level: LLTClassification code 10003445Term: AscitesMedDRA version: 9.1Level: LLTClassification code 10021038Term: HyponatremiaEUCTR2007-001711-31-DEMovetis NV12